Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Russell Jenkins
Massachusetts General Hospital, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
XSphera Biosciences Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Jenkins serves on the Scientific Advisory Board and is a co-founder of XSphera Biosciences Inc.; as such, he holds private equity in the company. XSphera Biosciences is focused on using ex vivo profiling technology, including organotypic tumor spheroids, to deliver functional, precision immune-oncology solutions for patients, providers, and drug development companies. The research seeks to use organotypic tumor spheroids to develop novel strategies to overcome resistance to PD-1 blockade; and, if successful, the company may have an interest in the resulting IP. The Partners Committee on Outside Activities reviewed the financial interest in connection with the research and determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research. The committee determined that the conflict could be managed with the implementation of an FCOI management plan.
Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor Spheroids
PROJECT NARRATIVE While immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have show unprecedented and durable clinical responses in melanoma and other cancers, resistance remains a challenge for the majority of patients and robust biomarkers to guide treatment are lacking. This project seeks to use murine- and patient- derived organotypic tumor spheroids (MDOTS/PDOTS) cultured in a 3-dimensional microfluidic system to develop novel strategies to overcome resistance to PD-1 blockade. Thus, the MDOTS/PDOTS platform represents a potential functional precision medicine platform for the development of novel combinations and ultimately personalized immunotherapy to tailor immunotherapy treatment to individual patients.
Filed on June 04, 2019.
Tell us what you know about Russell Jenkins's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.